

NOVEMBER 2009 PBAC MEETING OUTCOMES - Deferrals

DRUG AND FORM	DRUG USE AND TYPE	LISTING REQUESTED BY SPONSOR	PBAC OUTCOME AND COMMENT
Pemetrexed disodium, powder for IV infusion, 100 mg (base) and 500 mg (base), (Alimta®) Eli Lilly Australia Pty Ltd	Anti-cancer drug	Extend the current Authority Required listing to include first-line treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC) with predominantly non-squamous cell histology in combination with cisplatin.	The PBAC considered the incremental cost-effectiveness ratio to be high and uncertain, and deferred the submission to allow for further dialogue with the sponsor on several identified issues.
Major submission		Sponsor's comments:	Eli Lilly will continue to work with the PBAC to clarify the issues outstanding and work towards an acceptable positive recommendation